沃森生物：11月28日召开董事会会议

Group 1 - The core point of the article is that Watson Bio (SZ 300142) announced the convening of its 33rd board meeting for the year 2025, which will discuss the appointment of the auditing firm for the fiscal year [1] - For the first half of 2025, Watson Bio's revenue composition is as follows: self-developed vaccines account for 94.82%, intermediate product revenue accounts for 4.67%, other business accounts for 0.26%, and service revenue accounts for 0.24% [1] - As of the time of reporting, Watson Bio's market capitalization is 19.4 billion yuan [1]